journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/29145584/critical-lessons-from-high-value-oncology-practices
#1
Douglas W Blayney, Melora K Simon, Beatrice Podtschaske, Scott Ramsey, Margaret Shyu, Craig Lindquist, Arnold Milstein
Importance: Cancer care is expensive. Cancer care provided by practice organizations varies in total spending incurred by patients and payers during treatment episodes and in quality of care, and this unnecessary variation contributes to the high cost. Objective: To use the variation in total spending and quality of care to assess oncology practice attributes distinguishing "high value" that may be tested and adopted by others to produce similar results. Design, Setting, and Participants: "Positive deviance" was used in this exploratory mixed-methods (quantitative and qualitative) analysis of interview results...
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145574/rethinking-extended-adjuvant-antiestrogen-therapy-to-increase-survivorship-in-breast-cancer
#2
Balkees Abderrahman, V Craig Jordan
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145564/incorrect-percentages-in-the-abstract
#3
(no author information available yet)
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145560/strategies-to-achieve-high-value-oncology-care-a-beginning
#4
Harold C Sox, Ethan M Basch, Donald Berwick
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145547/association-of-first-in-class-immune-checkpoint-inhibition-and-targeted-therapy-with-survival-in-patients-with-stage-iv-melanoma
#5
Andrew J Sinnamon, Madalyn G Neuwirth, Phyllis A Gimotty, Tara C Gangadhar, Ravi K Amaravadi, Lynn M Schuchter, Giorgos C Karakousis
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145543/association-of-ipilimumab-with-safety-and-antitumor-activity-in-women-with-metastatic-or-recurrent-human-papillomavirus-related-cervical-carcinoma
#6
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, Mihaela C Cristea, Lainie P Martin, Katia Tonkin, Gini F Fleming, Anna V Tinker, Hal W Hirte, Daliah Tsoref, Helen Mackay, Neesha C Dhani, Prafull Ghatage, Johanne Weberpals, Stephen Welch, Nhu-An Pham, Vinicius Motta, Valentin Sotov, Lisa Wang, Katherine Karakasis, Smitha Udagani, Suzanne Kamel-Reid, Howard Z Streicher, Patricia Shaw, Amit M Oza
Importance: Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell immune response. Objective: To assess the safety and antitumor activity of ipilimumab in recurrent cervical cancer. Design, Setting, and Participants: A multicenter trial was designed for patients with metastatic cervical cancer (squamous cell carcinoma or adenocarcinoma) with measurable disease and progression after at least 1 line of platinum chemotherapy...
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29145542/gradually-worsening-pruritic-plaques
#7
Hoda Daher, Basim Towfiq, Samer Al Hadidi
No abstract text is available yet for this article.
November 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121177/out-of-pocket-and-health-care-spending-changes-for-patients-using-orally-administered-anticancer-therapy-after-adoption-of-state-parity-laws
#8
Stacie B Dusetzina, Haiden A Huskamp, Aaron N Winn, Ethan Basch, Nancy L Keating
Importance: Oral anticancer medications are increasingly important but costly treatment options for patients with cancer. By early 2017, 43 states and Washington, DC, had passed laws to ensure patients with private insurance enrolled in fully insured health plans pay no more for anticancer medications administered by mouth than anticancer medications administered by infusion. Federal legislation regarding this issue is currently pending. Despite their rapid acceptance, the changes associated with state adoption of oral chemotherapy parity laws have not been described...
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121150/issues-of-awareness-related-to-human-papillomavirus-infection-positivity-among-us-adult-men-reply
#9
Jasmine J Han, Thomas Beltran, John Song
No abstract text is available yet for this article.
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121148/issues-of-awareness-related-to-human-papillomavirus-infection-positivity-among-us-adult-men
#10
Mario R Castellanos, Maria A Farberov, Alia Kozlova
No abstract text is available yet for this article.
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121145/a-young-man-with-disseminated-intra-abdominal-masses
#11
Aung Myint Tun, Philip Xiao, Elizabeth Guevara
No abstract text is available yet for this article.
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121144/positron-emission-tomography-computed-tomography-based-assessments-of-androgen-receptor-expression-and-glycolytic-activity-as-a-prognostic-biomarker-for-metastatic-castration-resistant-prostate-cancer
#12
Josef J Fox, Somali C Gavane, Estelle Blanc-Autran, Sadek Nehmeh, Mithat Gönen, Brad Beattie, Hebert A Vargas, Heiko Schöder, John L Humm, Samson W Fine, Jason S Lewis, Stephen B Solomon, Joseph R Osborne, Darren Veach, Charles L Sawyers, Wolfgang A Weber, Howard I Scher, Michael J Morris, Steven M Larson
Importance: Androgen receptor-signaling inhibitor (ARSi) drugs prolong life in metastatic castration-resistant prostate cancer (mCRPC), but such tumors eventually become resistant and progress. Comprehensive positron emission tomography/computed tomography (PET/CT) imaging using fluoro-2-D-deoxyglucose F 18 ([18F]-FDG) for glycolysis (Glyc) and fluorodihydrotestosterone F 18 ([18F]-FDHT) for androgen receptor (AR) expression determine heterogeneity of imaging phenotypes, which may be useful in distinguishing patients who will benefit from ARSi drugs from those who need alternative treatments...
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121143/mismatch-repair-deficiency-testing-in-patients-with-colorectal-cancer-and-nonadherence-to-testing-guidelines-in-young-adults
#13
Talha Shaikh, Elizabeth A Handorf, Joshua E Meyer, Michael J Hall, Nestor F Esnaola
Importance: Mismatch repair (MMR) deficiency of DNA has been observed in up to 15% of sporadic colorectal cancers (CRCs) and is a characteristic feature of Lynch syndrome, which has a higher incidence in young adults (age, <50 years) with CRC. Mismatch repair deficiency can be due to germline mutations or epigenetic inactivation, affects prognosis and response to systemic therapy, and results in unrepaired repetitive DNA sequences, which increases the risk of multiple malignant tumors...
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121142/close-call
#14
Jane deLima Thomas
No abstract text is available yet for this article.
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29121141/status-of-testing-for-high-level-microsatellite-instability-deficient-mismatch-repair-in-colorectal-carcinoma
#15
Stanley R Hamilton
No abstract text is available yet for this article.
November 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098294/fiber-intake-and-survival-after-colorectal-cancer-diagnosis
#16
Mingyang Song, Kana Wu, Jeffrey A Meyerhardt, Shuji Ogino, Molin Wang, Charles S Fuchs, Edward L Giovannucci, Andrew T Chan
Importance: Although high dietary fiber intake has been associated with a lower risk of colorectal cancer (CRC), it remains unknown whether fiber benefits CRC survivors. Objective: To assess the association of postdiagnostic fiber intake with mortality. Design, Setting, and Participants: A total of 1575 health care professionals with stage I to III CRC were evaluated in 2 prospective cohorts, Nurses' Health Study and Health Professionals Follow-up Study...
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098284/association-of-alterations-in-main-driver-genes-with-outcomes-of-patients-with-resected-pancreatic-ductal-adenocarcinoma
#17
Zhi Rong Qian, Douglas A Rubinson, Jonathan A Nowak, Vicente Morales-Oyarvide, Richard F Dunne, Margaret M Kozak, Marisa W Welch, Lauren K Brais, Annacarolina Da Silva, Tingting Li, Wanwan Li, Atsuhiro Masuda, Juhong Yang, Yan Shi, Mancang Gu, Yohei Masugi, Justin Bui, Caitlin L Zellers, Chen Yuan, Ana Babic, Natalia Khalaf, Andrew Aguirre, Kimmie Ng, Rebecca A Miksad, Andrea J Bullock, Daniel T Chang, Jennifer F Tseng, Thomas E Clancy, David C Linehan, Jennifer J Findeis-Hosey, Leona A Doyle, Aaron R Thorner, Matthew Ducar, Bruce Wollison, Angelica Laing, William C Hahn, Matthew Meyerson, Charles S Fuchs, Shuji Ogino, Jason L Hornick, Aram F Hezel, Albert C Koong, Brian M Wolpin
Importance: Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes. Objective: To evaluate the alterations of the 4 main driver genes in pancreatic adenocarcinoma and patient outcomes after cancer resection. Design, Setting, and Participants: This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013)...
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098281/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer
#18
Koen G A M Hussaarts, Roelof W F van Leeuwen, Ron H J Mathijssen
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098276/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer
#19
Lishi Wang, Boern Shan, Weikuan Gu
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29098275/factors-affecting-the-association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer-reply
#20
Michael P Chu, Michael B Sawyer
No abstract text is available yet for this article.
November 2, 2017: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"